Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: A literature review

Pituitary

Volumn 14, Issue 2, 2011, Pages 184-193

  Fleseriu, Maria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Acromegaly; Dose optimization; Lanreotide Autogel ; Octreotide LAR

Indexed keywords

ANGIOPEPTIN; DOPASTATIN; GROWTH HORMONE; LIGAND; OCTREOTIDE; PASIREOTIDE; PLACEBO; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACROMEGALY; BILE DUCT OBSTRUCTION; BINDING AFFINITY; CANCER INHIBITION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; GALLBLADDER DISEASE; GALLSTONE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; LIGANDS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 79958171697     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0282-z     Document Type: Review

References (65)

1. Etxabe J, Gaztambide S, Latorre P, Vazquez JA (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16:181-187 (Pubitemid 23137956)
2. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29-41
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775 (Pubitemid 44917305)
4. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-2573
5. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61-67
6. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674 (Pubitemid 38269875)
7. Biermasz NR, Van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369-5376 (Pubitemid 39518410)
8. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95
9. AACE Acromegaly Guidelines Task Force (2004) AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10:213-225
10. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
11. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529 (Pubitemid 32273628)
12. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141-3148
13. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91 (Pubitemid 36098853)
14. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF (2003) Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572 (Pubitemid 37034496)
15. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152:379-387
16. Shimon I, Cohen ZR, Ram Z, Hadani M (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48:1239-1243
17. Fleseriu M, Delashaw JB, Cook DM (2010) Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 29:E15
18. Anthony L, Freda PU (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 25:2989-2999
19. Colao A, Cappabianca P, Caron P, De Menism E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC (2009) Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, openlabel, multicentre study. Clin Endocrinol (Oxf) 70:757-768
20. Murray RD, Kim K, Ren S-G, Chelly M, Umehara Y, Melmed S (2004) Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 114:349-356 (Pubitemid 39071607)
21. Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74
22. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12:297-303
23. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Y-Y, Hu K, Farrall AJ, Melmed S, Biller BM (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J Clin Endocrinol Metab 95:2781-2789
24. Wilson C (2010) Pharmacotherapy: Pasireotide shows promise for the treatment of acromegaly. Nat Rev Endocrinol 6:417
25. Colao A, Faggiano A, Pivonello R (2010) Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog Brain Res 182:281-294
26. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J (1997) Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 82:23-28 (Pubitemid 27021264)
27. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC (1995) Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267-3272
28. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99-104 (Pubitemid 34084677)
29. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:734-740 (Pubitemid 38788082)
30. Ronchi CL, Boschetti M, Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M (2007) Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 67:512-519 (Pubitemid 47416307)
31. Bevan JS, Atkin SL, Atkinson AB, Bouloux P-M, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin- like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
32. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786 (Pubitemid 32545739)
33. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G (2006) First-line octreotide-LAR therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 64:342-351
34. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098 (Pubitemid 36877477)
35. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
36. Lancranjan I, Atkinson AB (1999) Results of a European multicentre study with Sandostatin® LAR® in acromegalic patients. Sandostatin LAR group. Pituitary 1:105-114
37. Mercado M, Borges F, Bouterfa H, Chang T-C, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859-868
38. Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18-22 (Pubitemid 27021263)
39. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano DG (1997) Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277-284 (Pubitemid 27163251)
40. Colao A, Lombardi G (2010) Dose optimization of somatostatin analogues for acromegaly patients. J Endocrinol Invest 33:125-127
41. James RA, Gilroy J (2001) Dose and frequency titration of somatostatin analogues in the treatment of acromegaly - an injection of expediency? Clin Endocrinol (Oxf) 54:11-13
42. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB (2000) Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 53:719-724 (Pubitemid 32096683)
43. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740 (Pubitemid 43020222)
44. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely A-J (2009) Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69:2207-2226
45. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957-2968
46. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473 (Pubitemid 41159328)
47. Ayuk J, Sheppard MC (2006) Growth hormone and its disorders. Postgrad Med J 82:24-30 (Pubitemid 43111799)
48. Ayuk J, Sheppard MC (2008) Does acromegaly enhance mortality? Rev Endocr Metab Disord 9:33-39
49. Chanson P, Borson-Chazot F, Kuhn J-M, Blumberg J, Maisonobe P, Delemer B (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69:299-305 (Pubitemid 352009031)
50. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel((R)) therapy: a randomized, placebo- controlled, multicenter study with a 52 week open extension. Pituitary 13:18-28
51. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579-587 (Pubitemid 350187374)
52. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E,Minuto F, Lombardi G, Pivonello R, Ferone D (2009) Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71:237-245
53. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Longterm effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71 (Pubitemid 34107323)
54. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94:3746-3756
55. Mazziotti G, Giustina A (2010) Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13:60-67
56. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, De Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161:331-338
57. Wuster C, Both S, Cordes U, Omran W, Reisch R (2010) Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 4:85
58. Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De ME, Davi MV, Battista C, Castello R, Cremonini N, Razzore P, Rosato F, Montini M, Cozzi R (2008) Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 14:846-855
59. Toledano Y, Rot L, Greenman Y, Orlovsky S, Pauker Y, Olchovsky D, Eliash A, Bardicef O, Makhoul O, Tsvetov G, Gershinsky M, Cohen-Ouaqnine O, Ness-Abramof R, Adnan Z, Ilany J, Guttmann H, Sapir M, Benbassat C, Shimon I (2009) Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 12:285-293
60. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
61. Cozzi R, Attanasio R (2007) Octreotide for acromegaly. Expert Rev Endocrinol Metab 2:129-145
62. Baldelli R, Battista C, Leonetti F, Ghiggi M-R, Ribaudo M-C, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-499 (Pubitemid 37188181)
63. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508
64. Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P (2007) Forty-month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocr J 54:459-464 (Pubitemid 47105435)
65. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel((R)) therapy: a randomized, placebo- controlled, multicenter study with a 52 week open extension. Pituitary 13:18-28